サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1489248

製薬CDMOの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Pharmaceutical CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 170 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
製薬CDMOの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年05月01日
発行: Value Market Research
ページ情報: 英文 170 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

製薬CDMO市場の世界需要は、2023年の1,794億7,000万米ドルから2032年には約3,516億4,000万米ドルの市場規模に達すると推定され、調査期間2024-2032年のCAGRは7.76%です。

製薬CDMO（開発・製造受託機関）は、医薬品開発、製造、包装を含む包括的なサービスを製薬会社に提供します。これらの組織は、製剤化の初期段階から大規模な生産・流通に至るまで製薬企業をサポートします。CDMOは、臨床試験、規制遵守、品質管理など、医薬品ライフサイクルの様々な側面において専門知識を提供します。CDMOと提携することで、製薬会社は専門的な知識とインフラを活用し、医薬品製造における高い安全性と有効性基準を確保しながら、市場投入までの時間を短縮し、コストを削減することができます。

市場力学

製薬CDMO（開発・製造受託機関）市場の成長は、企業が業務の合理化、コスト削減、研究やマーケティングなどのコアコンピタンスへの集中を目指す中、医薬品アウトソーシングへの需要が高まっていることが背景にあります。医薬品開発は複雑で、専門的なスキルや設備が必要とされるため、多くの製薬企業が開発・製造工程をCDMOに依存しています。さらに、生物製剤やバイオシミラー医薬品の生産が増加したことで、製薬CDMOの需要が大幅に高まりました。これらの複雑な分子は、専門的な製造能力を必要とするからです。連続製造やシングルユース技術といった製造プロセスの技術的進歩が、CDMOの魅力をさらに高めています。

個別化医療やニッチ治療薬に向けた動向の高まりも、CDMOが提供できる柔軟でスケーラブルな製造ソリューションを必要とするため、市場成長に寄与しています。さらに、規制の圧力や厳しい品質基準への準拠の必要性から、CDMOはリスクを軽減し、製品の品質を確保しようとする製薬企業にとって魅力的な選択肢となっています。新興国市場における製薬産業の拡大と医薬品開発への投資の増加が、製薬CDMO市場を牽引しています。しかし、規制遵守の課題や競合からの圧力が、今後数年間の市場成長の課題となる可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を取り上げています。これらのツールは、業界構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは製薬CDMOの世界市場における各セグメントを包括的に評価することもできます。製薬CDMO業界の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおける製薬CDMO市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、著名な全地域にわたる個々のアプリケーションセグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 製薬CDMO-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 製薬CDMOの世界市場分析：用途別

  • 概要
  • 実績および予測データ分析
  • 感染症
  • 腫瘍学
  • 神経疾患

第6章 製薬CDMOの世界市場分析：ワークフロー別

  • 概要
  • 実績および予測データ分析
  • 商業
  • 臨床

第7章 製薬CDMOの世界市場分析：製品別

  • 概要
  • 実績および予測データ分析
  • 合成
  • 製造
  • 医薬品
  • 原薬

第8章 製薬CDMOの世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第9章 製薬CDMO企業の競合情勢

  • 製薬CDMO市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • WuXi AppTec
  • Catalent Inc.
  • AbbVie Contract Manufacturing
  • Lonza Group AG
  • Evonik Industries AG
  • Patheon
  • Siegfried Holding AG
  • Recipharm AB
  • Aenova Group
  • CordenPharma
  • Jubilant Life Sciences Ltd.
  • Almac Group
  • Piramal Pharma Solutions
  • Cambrex Corporation
  • Fareva
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Application (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Neurological Disorders Market Sales By Geography (USD MN)
  • Analysis By Workflow (USD MN)
  • Commercial Market Sales By Geography (USD MN)
  • Clinical Market Sales By Geography (USD MN)
  • Analysis By Product (USD MN)
  • Synthesis Market Sales By Geography (USD MN)
  • Manufacturing Market Sales By Geography (USD MN)
  • Drug Market Sales By Geography (USD MN)
  • API Market Sales By Geography (USD MN)
  • Global Pharmaceutical CDMO Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Pharmaceutical CDMO Report
  • Market Research Process
  • Market Research Methodology
  • Global Pharmaceutical CDMO Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By Workflow
  • Market Attractiveness Analysis By Product
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Application (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Neurological Disorders Market Sales By Geography (USD MN)
  • Global Market Analysis By Workflow (USD MN)
  • Commercial Market Sales By Geography (USD MN)
  • Clinical Market Sales By Geography (USD MN)
  • Global Market Analysis By Product (USD MN)
  • Synthesis Market Sales By Geography (USD MN)
  • Manufacturing Market Sales By Geography (USD MN)
  • Drug Market Sales By Geography (USD MN)
  • API Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112114744

The global demand for Pharmaceutical CDMO Market is presumed to reach the market size of nearly USD 351.64 Billion by 2032 from USD 179.47 Billion in 2023 with a CAGR of 7.76% under the study period 2024-2032.

A pharmaceutical CDMO (Contract Development and Manufacturing Organization) provides comprehensive services to pharmaceutical companies, including drug development, manufacturing, and packaging. These organizations support pharmaceutical firms from the initial stages of drug formulation to large-scale production and distribution. CDMOs offer expertise in various aspects of the drug lifecycle, including clinical trials, regulatory compliance, and quality control. Partnering with a CDMO allows pharmaceutical companies to leverage specialized knowledge and infrastructure, accelerating time-to-market and reducing costs while ensuring high safety and efficacy standards in drug production.

MARKET DYNAMICS

The growth of the pharmaceutical CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for pharmaceutical outsourcing, as companies seek to streamline operations, lower costs, and focus on core competencies such as research and marketing. The complexity of drug development and the need for specialized skills and equipment has led many pharmaceutical companies to rely on CDMOs for development and manufacturing processes. Additionally, the rise in biologics and biosimilar production has significantly boosted the demand for Pharmaceutical CDMOs, as these complex molecules require specialized manufacturing capabilities. Technological advancements in manufacturing processes, such as continuous manufacturing and single-use technologies, have further enhanced the appeal of CDMOs.

The growing trend towards personalized medicine and niche therapeutics also contributes to market growth, as these require flexible and scalable production solutions that CDMOs can provide. Moreover, regulatory pressures and the need for compliance with stringent quality standards make CDMOs an attractive option for pharmaceutical companies looking to mitigate risks and ensure product quality. The expanding pharmaceutical industry in emerging markets and increased investment in drug development drive the pharmaceutical CDMO market. However, regulatory compliance challenges and competitive pressures may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmaceutical CDMO. The growth and trends of Pharmaceutical CDMO industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmaceutical CDMO market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

  • Infectious Diseases
  • Oncology
  • Neurological Disorders

By Workflow

  • Commercial
  • Clinical

By Product

  • Synthesis
  • Manufacturing
  • Drug
  • API

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmaceutical CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmaceutical CDMO market include WuXi AppTec, Catalent Inc., AbbVie Contract Manufacturing, Lonza Group AG, Evonik Industries AG, Patheon, Siegfried Holding AG, Recipharm AB, Aenova Group, CordenPharma, Jubilant Life Sciences Ltd., Almac Group, Piramal Pharma Solutions, Cambrex Corporation, Fareva. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PHARMACEUTICAL CDMO - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Application
    • 3.7.2 Market Attractiveness Analysis By Workflow
    • 3.7.3 Market Attractiveness Analysis By Product
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY APPLICATION

  • 5.1. Overview By Application
  • 5.2. Historical and Forecast Data Analysis By Application
  • 5.3. Infectious Diseases Historic and Forecast Sales By Regions
  • 5.4. Oncology Historic and Forecast Sales By Regions
  • 5.5. Neurological Disorders Historic and Forecast Sales By Regions

6. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY WORKFLOW

  • 6.1. Overview By Workflow
  • 6.2. Historical and Forecast Data Analysis By Workflow
  • 6.3. Commercial Historic and Forecast Sales By Regions
  • 6.4. Clinical Historic and Forecast Sales By Regions

7. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY PRODUCT

  • 7.1. Overview By Product
  • 7.2. Historical and Forecast Data Analysis By Product
  • 7.3. Synthesis Historic and Forecast Sales By Regions
  • 7.4. Manufacturing Historic and Forecast Sales By Regions
  • 7.5. Drug Historic and Forecast Sales By Regions
  • 7.6. API Historic and Forecast Sales By Regions

8. GLOBAL PHARMACEUTICAL CDMO MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMACEUTICAL CDMO COMPANIES

  • 9.1. Pharmaceutical CDMO Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF PHARMACEUTICAL CDMO INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. WuXi AppTec
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Catalent Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. AbbVie Contract Manufacturing
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Lonza Group AG
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Evonik Industries AG
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Patheon
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Siegfried Holding AG
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Recipharm AB
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Aenova Group
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. CordenPharma
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Jubilant Life Sciences Ltd.
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. Almac Group
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments
  • 10.15. Piramal Pharma Solutions
    • 10.15.1 Company Overview
    • 10.15.2 Company Revenue
    • 10.15.3 Products
    • 10.15.4 Recent Developments
  • 10.16. Cambrex Corporation
    • 10.16.1 Company Overview
    • 10.16.2 Company Revenue
    • 10.16.3 Products
    • 10.16.4 Recent Developments
  • 10.17. Fareva
    • 10.17.1 Company Overview
    • 10.17.2 Company Revenue
    • 10.17.3 Products
    • 10.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies